Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
November 5, 2021 7:30 AM EDTFirst Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Study of SY-2101 in APL
Presented Phase 1 Data of SY-5609 at ESMO, Demonstrating Clinical Activity at Tolerable Doses and Supporting Development in Three Combination Regimens
Expanded Leadership Team with Key Appointments
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today... More
